LMR Partners’s Larimar Therapeutics LRMR Stock Holding History

LMR Partners’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-19,944	Closed	-$90.3K	–	1016
2023 Q1	$90.3K	Buy	+19,944	New	+$104K	﹤0.01%	949
2019 Q4	–	Sell	-2,094	Closed	-$19K	–	490
2019 Q3	$19K	Hold	2,094	–	–	﹤0.01%	399
2019 Q2	$30K	Buy	+2,094	New	+$55.8K	﹤0.01%	389
2017 Q3	–	Sell	-7,096	Closed	-$299K	–	458
2017 Q2	$299K	Buy	+7,096	New	+$363K	0.02%	476

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

LMR Partners's LRMR Position: Q2 2023 in Review

LMR Partners sold out of Larimar Therapeutics (LRMR) in Q2 2023, closing a stake of 19,944 shares — an estimated $90.3K sold.

LMR Partners first reported a position in LRMR in Q2 2017 and held it in 4 quarters. The position peaked at $299K in Q2 2017. 65 funds tracked by Wall St. Rank hold LRMR as of Q2 2023.

LMR Partners reported no remaining Larimar Therapeutics position as of Q2 2023 after selling out during the quarter.
LMR Partners sold 19,944 Larimar Therapeutics shares in Q2 2023, an estimated $90.3K.
LMR Partners first reported a position in Larimar Therapeutics in Q2 2017 and held it in 4 quarters.
LMR Partners's Larimar Therapeutics position peaked at $299K in Q2 2017.
65 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.